These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34565137)

  • 1. Genotype-specific versus pangenotypic regimens in patients infected with hepatitis C virus genotype 1b in real-world settings.
    Pabjan P; Brzdęk M; Chrapek M; Dziedzic K; Stępień PM; Paluch K; Garbat A; Błoniarczyk P; Reczko K; Zarębska-Michaluk D
    Pol Arch Intern Med; 2021 Nov; 131(11):. PubMed ID: 34565137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.
    Brzdęk M; Zarębska-Michaluk D; Rzymski P; Lorenc B; Kazek A; Tudrujek-Zdunek M; Janocha-Litwin J; Mazur W; Dybowska D; Berak H; Parfieniuk-Kowerda A; Klapaczyński J; Sitko M; Sobala-Szczygieł B; Piekarska A; Flisiak R
    World J Gastroenterol; 2023 Apr; 29(13):2015-2033. PubMed ID: 37155527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.
    Tronina O; Brzdęk M; Zarębska-Michaluk D; Dybowska D; Lorenc B; Janczewska E; Mazur W; Parfieniuk-Kowerda A; Piekarska A; Krygier R; Klapaczyński J; Berak H; Jaroszewicz J; Garlicki A; Tomasiewicz K; Citko J; Flisiak R
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies.
    Jaroszewicz J; Zarębska-Michaluk D; Janocha-Litwin J; Parfieniuk-Kowerda A; Sitko M; Piekarska A; Białkowska J; Dybowska D; Murawska-Ochab A; Flisiak R
    Pol Arch Intern Med; 2023 Mar; 133(3):. PubMed ID: 36602060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy.
    Zarębska-Michaluk D; Buczyńska I; Simon K; Tudrujek-Zdunek M; Janczewska E; Dybowska D; Sitko M; Dobracka B; Jaroszewicz J; Pabjan P; Klapaczyński J; Laurans Ł; Mazur W; Socha Ł; Tronina O; Parczewski M; Flisiak R
    Can J Gastroenterol Hepatol; 2019; 2019():4029541. PubMed ID: 30941326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
    Ding YJ; Lu CK; Chen WM; Tung SY; Wei KL; Shen CH; Hsieh YY; Yen CW; Chang KC; Chiu WN; Hung CH; Lu SN; Chang TS
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2911-2916. PubMed ID: 33978973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
    Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
    World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
    Pabjan P; Brzdęk M; Chrapek M; Dziedzic K; Dobrowolska K; Paluch K; Garbat A; Błoniarczyk P; Reczko K; Stępień P; Zarębska-Michaluk D
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
    Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
    Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
    Zarębska-Michaluk D; Jaroszewicz J; Pabjan P; Łapiński TW; Mazur W; Krygier R; Dybowska D; Halota W; Pawłowska M; Janczewska E; Buczyńska I; Simon K; Dobracka B; Citko J; Laurans Ł; Tudrujek-Zdunek M; Tomasiewicz K; Piekarska A; Sitko M; Białkowska-Warzecha J; Klapaczyński J; Sobala-Szczygieł B; Horban A; Berak H; Deroń Z; Lorenc B; Socha Ł; Tronina O; Flisiak R
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1944-1952. PubMed ID: 33171526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection.
    Scotto R; Buonomo AR; Moriello NS; Maraolo AE; Zappulo E; Pinchera B; Gentile I; Borgia G
    Rev Recent Clin Trials; 2019; 14(3):173-182. PubMed ID: 30848211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
    Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
    J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.
    Sun HY; Cheng CY; Lin CY; Yang CJ; Lee NY; Liou BH; Tang HJ; Liu YM; Lee CY; Chen TC; Huang YC; Lee YT; Tsai MJ; Lu PL; Tsai HC; Wang NC; Hung TC; Cheng SH; Hung CC
    World J Gastroenterol; 2022 Mar; 28(11):1172-1183. PubMed ID: 35431505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and antiviral therapy in patients infected with hepatitis C virus in the interferon‑free era.
    Brzdęk M; Dobrowolska K; Pabjan P; Zarębska-Michaluk D
    Pol Arch Intern Med; 2022 Sep; 132(9):. PubMed ID: 35938950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
    Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
    Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.
    Brzdęk M; Zarębska-Michaluk D; Invernizzi F; Cilla M; Dobrowolska K; Flisiak R
    World J Gastroenterol; 2023 Feb; 29(6):949-966. PubMed ID: 36844142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.